Multiple early-stage CTs of the first-in-class anti-DLL4 antibody demcizumab (OMP-21M18) in combination with other chemotherapeutic drugs have been registered: demcizumab + gemcitabine + nab-paclitaxel in pancreatic cancer (NCT01189929), demcizumab + FOLFIRI in colorectal cancer (NCT01189942), demcizumab + carboplatin + pemetrexed in NSCLC (NCT01189968), demcizumab + paclitaxel in patients with platinum-resistant ovarian cancer (NCT01952249). Here, DLL4 is linked to familial pancreatic carcinoma.